Hikma launches therapeutic heparin in the US market

EATONTOWN, NJ, 5 September, 2011 — Hikma Pharmaceuticals, PLC, (LON: HIK)(Nasdaq Dubai: HIK) and its wholly‐owned subsidiary, West‐Ward Pharmaceuticals, today announced the US launch of therapeutic heparin in single‐ and multiple‐dose vials.

Press Release Product 5 September 2011

Heparin is used to prevent clot formation in central venous catheters and for anticoagulant (blood thinning) therapy, and is available in numerous delivery systems for different modes of administration. Hikma’s five new vial presentations of heparin range in volume from 1 milliliter (mL) to 30 mL, and in concentration from 1,000 units per mL to 10,000 units per mL.

Hikma recognizes the clinical need for this important medication and is pleased to be introducing this high-quality, US manufactured product in which all porcine derived materials are exclusively from the US and Canada.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.